Diana Apetauerova, MD
Neurology · Burlington, MANPI 1861564346
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,400 of the $1,632 with a category attached, or 85.8%. AbbVie accounts for 85.8% of it on its own, with 2 other manufacturers making up the rest.
Across 3 payments — averaging $544.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Abbott$212
- Cala Health, Inc.$20
Across 66 payments — averaging $2137.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$79K
- Biohaven Pharmaceuticals, Inc.$26K
- Biogen$24K
- Biohaven Pharmaceutical Holding Company Ltd.$12K
What the payments were for
- Consulting fees$1,40086%
- Food & beverage$23214%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $1,400 |
| Abbott | 1 | $212 |
| Cala Health, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,632 in reported general payments places this provider in the 60th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 26 | $207,552 |
| RytaryCarbidopa/Levodopa | 85 | $118,659 |
| GocovriAmantadine Hcl | 32 | $89,880 |
| NourianzIstradefylline | 12 | $22,012 |
| Rasagiline Mesylate | 76 | $17,888 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 371 | $13,346 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 240 | $10,905 |
| Pramipexole ErPramipexole Di-Hcl | 17 | $8,704 |
| Entacapone | 32 | $6,053 |
| RivastigmineRivastigmine Tartrate | 64 | $5,755 |
| Carbidopa | 13 | $5,538 |
| AmantadineAmantadine Hcl | 55 | $2,418 |
| Propranolol Hcl | 70 | $2,116 |
| Ropinirole ErRopinirole Hcl | 23 | $1,958 |
| Selegiline Hcl | 15 | $1,192 |
Paid to pharmacies, not to this prescriber.
Other neurology in Burlington
- Thanh NguyenBurlington$102K
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Egilius SpieringsWellesley Hills$680K
- Thomas ScammellBoston$617K
- Salvatore NapoliFoxboro$613K
- Alfred SandrockBoston$490K
- Joshua KatzWellesley$462K
- Guy BuckleBrookline$450K
- Pushpa NarayanaswamiBoston$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.